GlassScriptPhysician profile
Jennifer Johnson
NPI 1346792397
$1,981.91
in general payments reported to CMS, 2019-2025
17 companies · $609 in 2025
The $609 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $530 · 2023: $494 · 2024: $348 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $320.06 | 2022-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $310.26 | 2022-2025 | Kisunla, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.07 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $158.66 | 2025 | Auvelity |
| Exact Sciences Corporation | $156.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $122.84 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $108.98 | 2022-2025 | |
| Novo Nordisk INC | $95.77 | 2022-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $89.71 | 2022-2023 | |
| Astellas Pharma US INC | $78.17 | 2023-2024 | Veozah |
| Baxter Healthcare | $73.50 | 2022 | |
| Amgen INC. | $69.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $57.76 | 2023-2024 | Rexulti |
| Pfizer INC. | $54.87 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $30.33 | 2022-2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $26.89 | 2022-2023 | Immunocap |
| Corcept Therapeutics | $22.25 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.